Dr Lal Pathlabs Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹731Cr
- +10.8% YoY
- +9.1% QoQ
- Net profit
- ₹152Cr
- +16% YoY
- +13.4% QoQ
- Margin
- 31%
- 0 pp YoY
- +2 pp QoQ
Guidance rank: #24 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
The company targets revenue growth in the range of 11% to 12% for FY26, maintaining this guidance as of now. The company is targeting a revenue growth range of 11%-12% for FY26 and aims to sustain this trajectory.
From Dr Lal Pathlabs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets revenue growth in the range of 11% to 12% for FY26, maintaining this guidance as of now.
- Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient.
- Growth drivers include testing network expansion, Swasthfit bundling, portfolio test mix improvement, and geographic and channel mix enhancements.
- Expansion focus remains on Delhi NCR and Tier-2/3/4 towns for future scalability.
- Pilots for radiology services are underway, with potential growth in integrated diagnostics.
- New super specialty testing capabilities are being developed to enhance portfolio complexity and differentiation.
2 more points from Dr Lal Pathlabs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dr Lal Pathlabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned CAPEX for the current year is estimated around Rs. 130-140 crore, including:
- Maintenance CAPEX of Rs. 50-60 crore.
- Purchase of a new property (Shalimar Bagh) focused on enhancing super specialty testing capabilities.
- Addition of 15 to 20 new labs this financial year.
- Expansion of collection centers by 600 to 800 new points this financial year.
- Radiology pilot program:
- Initial outlay for each pilot radiology center (including MRI and CT) between Rs. 12-15 crore.
2 more points from Dr Lal Pathlabs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Lal Pathlabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Dr Lal Pathlabs Ltd's call on order book
Create a free account to keep reading this call
Dr Lal Pathlabs Ltd — Quarterly revenue & net profit
Dr Lal Pathlabs Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 731 | 660 | +10.8% | 670 | +9.1% |
| Operating profit (EBITDA) | 224 | 202 | +10.9% | 192 | +16.7% |
| Operating margin | 31% | 31% | 0 pp | 29% | +2 pp |
| Profit before tax | 204 | 183 | +11.5% | 181 | +12.7% |
| Net profit (PAT) | 152 | 131 | +16% | 134 | +13.4% |
| EPS (₹) | 8.99 | 7.73 | +16.3% | 7.90 | +13.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹874 Cr, net profit ₹194 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Lal Pathlabs's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medicare (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dr Lal Pathlabs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Lal Pathlabs Ltd Q2 FY26 results?
The company targets revenue growth in the range of 11% to 12% for FY26, maintaining this guidance as of now. The company is targeting a revenue growth range of 11%-12% for FY26 and aims to sustain this trajectory.
What is Dr Lal Pathlabs Ltd share price analysis?
Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs Ltd planning capital expenditure?
Planned CAPEX for the current year is estimated around Rs. 130-140 crore, including:.
Keep Dr Lal Pathlabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
